Latest Biotech News

Corcept Therapeutics reported that relacorilant, its oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a Phase III ovarian cancer trial when added to chemotherapy....

Moderna told Bloomberg it is pulling back on investments in late‑stage vaccine trials in response to political backlash in the United States, shifting its R&D focus away from newer...

Genomics pioneer J. Craig Venter co‑founded Diploid Genomics, a new AI‑driven genomics analytics company backed by Healthier Capital, aiming to combine long‑read sequencing, imaging and AI to...

The National Institutes of Health announced it will stop supporting research using fetal human tissue, a move characterized by some scientists and advocacy groups as political rather than...

Swiss company 4bases and University of Florence launched clinical pilot studies to validate a nanopore‑based cytogenetics workflow, KaryoSolver, for rapid copy‑number variation detection in...

Erasca announced the closing of an upsized public offering that sold 25,875,000 shares at $10.00 each, including full exercise of the underwriters’ option. The company reported gross proceeds of...

Corxel Pharmaceuticals completed a $287 million Series D to advance CX‑11, an oral GLP‑1 receptor agonist licensed from Vincentage, through planned global Phase II and preparatory Phase III work....

NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The multi-year partnership will combine NVIDIA’s compute...

Guardant Health secured FDA approval for its Guardant360 CDx blood test as a companion diagnostic to identify BRAF V600E‑mutant metastatic colorectal cancer patients eligible for Pfizer’s...

Janux Therapeutics entered an exclusive collaboration and licensing agreement with Bristol Myers Squibb to develop tumor‑activated therapeutics derived from Janux’s TRACTr platform. Financial...

Corcept reported a 35% reduction in risk of death when relacorilant was added to chemotherapy in platinum‑resistant ovarian cancer, meeting an overall survival endpoint in the Phase III study. The...

Researchers at the Icahn School of Medicine at Mount Sinai developed IL‑12‑producing CAR‑T cells that target tumor‑associated macrophages (TAMs) rather than cancer cells directly. In aggressive...

A genome‑wide screen at A*STAR IMCB uncovered a P2Y2‑integrin β1 axis that stabilizes mutant EGFR proteins in non‑small cell lung cancer. The team showed that tumor cells secrete ATP to activate...

Encodia, a San Diego firm developing DNA‑tagged peptide protein sequencing (ProteoCode), ceased operations late last year and filed an assignment for the benefit of creditors on Nov. 7, 2025,...

Moderna’s CEO told Bloomberg TV the company will scale back investments in late‑stage infectious‑disease vaccine trials amid mounting public and political backlash in the United States. The...

NVIDIA and Eli Lilly announced a joint $1 billion laboratory in the San Francisco Bay Area to deploy AI at scale across drug discovery and development. The partnership will combine NVIDIA’s...

Genomics pioneer J. Craig Venter and cofounders launched Diploid Genomics with seed backing from Healthier Capital to build an AI‑driven genomics analytics company. The San Diego spinout said it...

Corxel Pharmaceuticals closed a $287 million Series D to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist, through ongoing U.S. phase II trials and planned global phase II studies, and...

A team of former BioMarin executives launched Mendra and closed an $82 million Series A to acquire, develop and commercialize therapies for rare diseases. Mendra will use AI to prioritize asset...

Janux Therapeutics announced an exclusive worldwide license and collaboration with Bristol Myers Squibb to develop tumor‑activated therapeutics from Janux’s TRACTr and related platforms. The...